NO943739L - Vaksiner inneholdende vesikler basert på ikke-ioniske overflate-aktive midler - Google Patents

Vaksiner inneholdende vesikler basert på ikke-ioniske overflate-aktive midler

Info

Publication number
NO943739L
NO943739L NO943739A NO943739A NO943739L NO 943739 L NO943739 L NO 943739L NO 943739 A NO943739 A NO 943739A NO 943739 A NO943739 A NO 943739A NO 943739 L NO943739 L NO 943739L
Authority
NO
Norway
Prior art keywords
nonionic surfactants
vesicles
vaccines containing
containing vesicles
vesicles based
Prior art date
Application number
NO943739A
Other languages
English (en)
Other versions
NO943739D0 (no
Inventor
James Alexander
James Macdonald Brewer
Original Assignee
Proteus Molecular Design
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteus Molecular Design filed Critical Proteus Molecular Design
Publication of NO943739L publication Critical patent/NO943739L/no
Publication of NO943739D0 publication Critical patent/NO943739D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45Toxoplasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Vesikler basert på ikke-ioniske overflate-aktive midler (NSIV) med innesluttet antigen, virker som potente immuno- logiske adjuvanser og kan frembringe antistoff-titere av samme størrelsesorden som de hvor Freunds' komplette adjuvans benyttes. Oppfinnelsen tilveiebringer vaksiner som omfatter slike vesikler. Fortrinnsvis er de ikke-ioniske overflate- aktive midlene glycerolestere, særlig 1-monopalmitoylglycerol. Vesiklene kan administreres ved injeksjon eller via slim- hinner, hvorav peroral administrering foretrekkes.
NO943739A 1992-04-07 1994-10-05 Vaksiner inneholdende ikke-ioniske overflate-aktive vaksiner NO943739D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207731A GB9207731D0 (en) 1992-04-07 1992-04-07 Improvements in or relating to vaccines
PCT/GB1993/000716 WO1993019781A1 (en) 1992-04-07 1993-04-06 Vaccines containing non-ionic surfactant vesicles

Publications (2)

Publication Number Publication Date
NO943739L true NO943739L (no) 1994-10-05
NO943739D0 NO943739D0 (no) 1994-10-05

Family

ID=10713695

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943739A NO943739D0 (no) 1992-04-07 1994-10-05 Vaksiner inneholdende ikke-ioniske overflate-aktive vaksiner

Country Status (16)

Country Link
US (1) US5679355A (no)
EP (1) EP0634937B1 (no)
JP (1) JP2690620B2 (no)
KR (1) KR950700758A (no)
CN (1) CN1085449A (no)
AT (1) ATE158185T1 (no)
AU (1) AU3899793A (no)
CA (1) CA2132547C (no)
DE (1) DE69314020T2 (no)
FI (1) FI944676A7 (no)
GB (1) GB9207731D0 (no)
HU (1) HUT69935A (no)
NO (1) NO943739D0 (no)
NZ (1) NZ251402A (no)
WO (1) WO1993019781A1 (no)
ZA (1) ZA932491B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
JPH09510433A (ja) * 1993-12-17 1997-10-21 マイクロパック インコーポレイテッド 生物学的に活性な物質を細胞に送達する方法
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9515868D0 (en) * 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9600471D0 (en) * 1996-01-10 1996-03-13 Univ London Pharmacy Drug delivery system
IL138000A0 (en) * 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2802422B1 (fr) * 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
FI112825B (fi) * 2001-07-11 2004-01-15 Antti Nissinen Menetelmä alkoholinkulutuksen osoittamiseksi, menetelmässä käytettäviä välineitä sekä niiden valmistus
US20040208920A1 (en) * 2002-07-03 2004-10-21 Dov Michaeli Liposomal vaccine
WO2004045583A1 (ja) * 2002-11-15 2004-06-03 Nipro Corporation リポソーム
FR2850872A1 (fr) * 2003-02-12 2004-08-13 Ethypharm Sa Composition vaccinale destinee a induire une reponse immunitaire contre le virus responsable du sida
BRPI0414021B1 (pt) 2003-08-28 2023-09-26 Becton, Dickinson And Company Dispositivo de injeção intradérmica
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2009155489A2 (en) 2008-06-19 2009-12-23 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
EP2644227B1 (en) 2008-07-30 2016-12-28 Ecole Polytechnique Fédérale de Lausanne Apparatus for optimized stimulation of a neurological target
CA2743575C (en) 2008-11-12 2017-01-31 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2782710C (en) 2009-12-01 2019-01-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device and methods of making and using the same
EP2552536B1 (en) 2010-04-01 2016-06-08 Ecole Polytechnique Fédérale de Lausanne (EPFL) Device for interacting with neurological tissue
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
US9506933B2 (en) 2011-01-07 2016-11-29 Toagosei Co., Ltd. Method of preparing antigen for acquiring anti-hydrophobic peptide antibody
WO2012093733A1 (ja) * 2011-01-07 2012-07-12 セイコーエプソン株式会社 抗シグナルペプチド抗体の製造方法
CA2862871C (en) * 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) * 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 2型tnf受容体の発現を抑制する合成ペプチド及びその利用
WO2015173787A1 (en) 2014-05-16 2015-11-19 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
WO2017134587A1 (en) 2016-02-02 2017-08-10 Aleva Neurotherapeutics, Sa Treatment of autoimmune diseases with deep brain stimulation
GB201612108D0 (en) * 2016-07-12 2016-08-24 Univ Strathclyde Preperation of non-ionic surfactant vesicles and variants
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2597346B1 (fr) * 1986-04-22 1989-08-18 Oreal Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
DE3867635D1 (de) * 1987-03-13 1992-02-20 Micro Vesicular Systems Lipidversikel aus grenzflaechenaktiven stoffen und sterolen.
US4855090A (en) * 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
LU87449A1 (fr) * 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
WO1992017179A1 (en) * 1991-03-28 1992-10-15 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions

Also Published As

Publication number Publication date
HU9402904D0 (en) 1995-01-30
FI944676A0 (fi) 1994-10-06
EP0634937B1 (en) 1997-09-17
CA2132547A1 (en) 1993-10-14
CA2132547C (en) 2000-06-06
EP0634937A1 (en) 1995-01-25
US5679355A (en) 1997-10-21
WO1993019781A1 (en) 1993-10-14
NO943739D0 (no) 1994-10-05
DE69314020T2 (de) 1998-08-06
JP2690620B2 (ja) 1997-12-10
AU3899793A (en) 1993-11-08
JPH07505389A (ja) 1995-06-15
CN1085449A (zh) 1994-04-20
ZA932491B (en) 1993-11-02
NZ251402A (en) 1996-10-28
ATE158185T1 (de) 1997-10-15
GB9207731D0 (en) 1992-05-27
KR950700758A (ko) 1995-02-20
FI944676L (fi) 1994-10-06
HUT69935A (en) 1995-09-28
DE69314020D1 (de) 1997-10-23
FI944676A7 (fi) 1994-10-06

Similar Documents

Publication Publication Date Title
NO943739L (no) Vaksiner inneholdende vesikler basert på ikke-ioniske overflate-aktive midler
RU94046145A (ru) Комбинированные вакцины, содержащие поверхностный антиген гепатита в и другие антигены, способ их получения, способ предупреждения инфекций гепатита в
RU94042386A (ru) Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
FI951535A0 (fi) Immunogeeninen meningokokki -LPS ja siitä saadut ulkomembraanirakkulat ja rokote
NO912369D0 (no) Meningokokk-klasse-1-ytre-membranvaksine.
MY134811A (en) A vaccine composition comprising an antigen, a saponin and a sterol
AU1934088A (en) Saponin adjuvant
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
ATE153071T1 (de) Neue proteinhaltige partikeln
DE69527986D1 (de) Antigene arznei zur behandlung oder vorbeugung
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
FI924457A0 (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
DE69420970D1 (de) Impfstoff zubereitungen
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
KR930700544A (ko) 열대열말라리아원충의 16kDa의 표면 단백질
CA2273922A1 (en) Novel saponin compositions and uses thereof
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
CA2133441A1 (en) Haemophilus somnus immunogenic proteins
DE69322960D1 (de) Empfängnisverhütender impfstoff
CA2007248A1 (en) Meningococcal class 1 outer-membrane protein vaccine
IT8821666A0 (it) Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
MX9710523A (es) Vacunas contra hepatitis c.
TH32433A (th) " วัคซีน "